Obesity-associated liver disease

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 11 SUPPL. 1, 2008, Pages

  Marchesini, Giulio ^a,b   Moscatiello, Simona ^a   Di Domizio, Silvia ^a   Forlani, Gabriele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; FATTY ACID; GAMMA GLUTAMYLTRANSFERASE; INSULIN SENSITIZING AGENT; INTERFERON; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

BARIATRIC SURGERY; BODY MASS; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; FATTY LIVER; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 55849127739     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1399     Document Type: Review

References (74)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ 1980 Nonalcoholic steatohepatitis: Mayo Clinic experience with an hitherto unnamed disease. Mayo Clin Proc 55:434-438
2. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW 1990 The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74-80
3. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Dore CJ, Goldin RD, Bell JD, Taylor-Robinson SD 2005 Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 54:122-127
4. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferranninni E, Rizzetto M 2005 Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48:634-642
5. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ 2005 Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343-1351
6. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C 2008 Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14:72-81
7. Kershaw EE, Flier JS 2004 Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548-2556
8. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW 2004 Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145:2273-2282
9. Trayhurn P, Wood IS 2004 Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347-355
10. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM 2007 Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45:1366-1374
11. Andersen T, Christoffersen P, Gluud C 1984 The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. Int J Obes 8:107-115
12. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C 2000 Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132:112-117
13. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S 2005 Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42:44-52
14. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH 2004 Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-1395
15. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Keum DK, Kim BI 2006 Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 21:138-143
16. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T 2007 The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102:2708-2715
17. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K 2005 The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143:722-728
18. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R 2006 Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 26:856-863
19. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ 2003 Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37:1286-1292
20. Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H, Ohba K, Isomoto H, Mizuta Y, Hayashida K, Murase K, Kadota T, Murata I, Kohno S 2002 Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 17:1098-1105
21. Clark JM, Brancati FL, Diehl AM 2003 The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98:960-967
22. Ruhl CE, Everhart JE 2003 Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124:71-79
23. Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, Nochajski TH, Trevisan M 2004 Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology 39:754-763
24. Marchesini G, Avagnina S, Barantani EG, Ciccarone AM, Corica F, Dall'Aglio E, Dalle Grave R, Morpurgo P, Tomasi F, Vitacolonna E 2005 Aminotransferase and γ-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest 28:333-339
25. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M 2003 Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917-923
26. Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, Lindor K 2005 Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 41:64-71
27. Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA 2003 Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 125:1053-1059
28. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ 2003 Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-1638
29. Nair S, Mason A, Eason J, Loss G, Perrillo RP 2002 Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 36:150-155
30. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM 2004 Obesity and hepatocellular carcinoma. Gastroenterology 127:S97-S103
31. Yang S, Lin HZ, Hwang J, Chacko VP, Diehl AM 2001 Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 61:5016-5023
32. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG 1999 Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84:1513-1517
33. Dixon JB, Bhathal PS, O'Brien PE 2001 Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91-100
34. Mathurin P, Gonzalez F, Kerdraon O, Leteurtre E, Arnalsteen L, Hollebecque A, Louvet A, Dharancy S, Cocq P, Jany T, Boitard J, Deltenre P, Romon M, Pattou F 2006 The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 130:1617-1624
35. Machado M, Marques-Vidal P, Cortez-Pinto H 2006 Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 45:600-606
36. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM 2005 Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 15:310-315
37. Klein S, Mittendorfer B, Eagon JC, Patterson B, Grant L, Feirt N, Seki E, Brenner D, Korenblat K, McCrea J 2006 Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 130:1564-1572
38. Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB 2008 A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 47:1916-1923
39. Marchesini G, Forlani G, Bugianesi E 2005 Is liver disease a threat to patients with metabolic disorders? Ann Med 37:333-346
40. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T 2000 Liver fibrosis in overweight patients. Gastroenterology 118:1117-1123
41. Angulo P, Keach JC, Batts KP, Lindor KD 1999 Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30:1356-1362
42. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y 2007 Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 22:1086-1091
43. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M 2004 Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39:179-187
44. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P 2003 A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38:257-265
45. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ 1999 Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29:664-669
46. Poonawala A, Nair SP, Thuluvath PJ 2000 Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32:689-692
47. Sakugawa H, Nakasone H, Nakayoshi T, Kawakami Y, Yamashiro T, Maeshiro T, Kobashigawa K, Kinjo F, Saito A 2003 Clinical characteristics of patients with cryptogenic liver cirrhosis in Okinawa, Japan. Hepatogastroenterology 50:2005-2008
48. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N 2001 Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 7:797-801
49. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M 2002 Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134-140
50. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, Poynard T 2002 Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35:1485-1493
51. Teli MR, James OF, Burt AD, Bennett MK, Day CP 1995 The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22:1714-1719
52. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C 2004 Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40:820-826
53. Adams LA, Sanderson S, Lindor KD, Angulo P 2005 The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42:132-138
54. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P 2005 The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129:113-121
55. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S 2006 Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865-873
56. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP 2004 Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 126:586-597
57. Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, Mills AS 2003 Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 98:2064-2071
58. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A, Negro F 2004 Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 53:406-412
59. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL 2002 Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 36:729-736
60. Negro F 2002 Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always. Hepatology 36:1050-1052
61. Bressler BL, Guindi M, Tomlinson G, Heathcote J 2003 High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38:639-644
62. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, Munoz-DeRueda P, Lopez-Serrano P, Gila A, Gutierrez ML, Perez C, Ruiz-Extremera A, Suarez E, Castillo J 2005 Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636-641
63. Adinolfi LE, Utili R, Ruggiero G 1999 Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients. Hepatology 30:1530-1531
64. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE 1999 Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29:1215-1219
65. Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM, Dhumeaux D 2003 Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52:288-292
66. Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, Layden TJ 1997 Effect of obesity on pharmacokinetics and biologic effect of interferon-α in hepatitis C. Dig Dis Sci 42:178-185
67. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F, for the HCV MAID Study Group 2006 Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130:1346-1362
68. Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE 2008 Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 48:80-87
69. Farrell GC, Larter CZ 2006 Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 43:S99-S112
70. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP 2006 Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 43:1145-1151
71. Sattar N, McConnachie A, Ford I, Gaw A, Cleland SJ, Forouhi NG, McFarlane P, Shepherd J, Cobbe S, Packard C 2007 Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 56:984-991
72. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G 2005 Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54:3541-3546
73. Targher G, Arcaro G 2007 Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 191:235-240
74. Bellentani S, Dalle Grave R, Suppini A, Marchesini G 2008 Behavior therapy in nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 47:746-754